Resource-Adapted Molecular Grouping of Medulloblastoma Using an Extended Immunohistochemical Panel: Correlation with DNA Methylation Profiling

Background Accurate molecular grouping of medulloblastoma is essential for integrated diagnosis and risk stratification but genome-wide DNA methylation profiling remains inaccessible in many resource-constrained settings. Immunohistochemistry (IHC) offers a practical surrogate, but the diagnostic boundaries of conventional panels and the added value of extended marker combinations remain incompletely defined. Methods We retrospectively evaluated 62 medulloblastoma cases from a tertiary neuropathology center. A routine 3-marker IHC panel (β-catenin, GAB1, YAP1) and an extended 7-marker panel (β-catenin, GAB1, YAP1, LEF1, OTX2, Filamin A, p75-NGFR) were compared against DNA methylation profiling as the reference standard in 51 methylation-confirmed cases. MYC/MYCN status was assessed by IHC, FISH and methylation-derived copy-number analysis. Survival analysis was performed using the Kaplan–Meier method. Results Methylation profiling confirmed medulloblastoma in 51/52 cases; one case was reclassified as diffuse paediatric-type high-grade glioma, MYCN subtype. Among 51 methylation-confirmed cases, non-WNT/non-SHH tumors predominated (29/51; 56.9%), followed by SHH-activated (14/51; 27.5%) and WNT-activated (8/51; 15.7%). The routine three-marker panel (β-catenin/GAB1/YAP1) achieved 88.2% concordance (45/51), misclassifying 4 WNT-activated and 2 SHH-activated tumors. The extended seven-marker panel achieved 100% concordance (51/51) in this cohort, correctly assigning all molecular groups. LEF1 outperformed β-catenin for WNT detection (sensitivity 100% vs 50%). A minimal LEF1/GAB1 backbone achieved 98.0% concordance (50/51). MYC amplification was identified in 1/51 cases and MYCN amplification in 2/51 cases; FISH showed complete concordance with methylation-derived copy-number analysis. Conclusion An extended, stringently interpreted IHC panel provides accurate molecular grouping of medulloblastoma and represents a practical, resource-adapted diagnostic strategy where methylation profiling is not routinely feasible.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2026-11-19
DOI
https://doi.org/10.1093/noajnl/vdag282
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Resource-Adapted Molecular Grouping of Medulloblastoma Using an Extended Immunohistochemical Panel: Correlation with DNA Methylation Profiling

Mariya Varghese, Ajay Kumar Garg, Chitra Sarkar, Srinidhi Vasant et al.
Neuro-Oncology Advances
Glioma Diagnosis and Treatment
article

Resource-Adapted Molecular Grouping of Medulloblastoma Using an Extended Immunohistochemical Panel: Correlation with DNA Methylation Profiling

Mariya Varghese, Ajay Kumar Garg, Chitra Sarkar, Srinidhi Vasant, Vaishali S. Suri, Swati Mahajan, Ashish Suri, Shabnam Mansoori, Kirti Srivastava, Ashwinee Kumar, Jyotsna Singh, Aanchal Verma
article en

Abstract

Background Accurate molecular grouping of medulloblastoma is essential for integrated diagnosis and risk stratification but genome-wide DNA methylation profiling remains inaccessible in many resource-constrained settings. Immunohistochemistry (IHC) offers a practical surrogate, but the diagnostic boundaries of conventional panels and the added value of extended marker combinations remain incompletely defined. Methods We retrospectively evaluated 62 medulloblastoma cases from a tertiary neuropathology center. A routine 3-marker IHC panel (β-catenin, GAB1, YAP1) and an extended 7-marker panel (β-catenin, GAB1, YAP1, LEF1, OTX2, Filamin A, p75-NGFR) were compared against DNA methylation profiling as the reference standard in 51 methylation-confirmed cases. MYC/MYCN status was assessed by IHC, FISH and methylation-derived copy-number analysis. Survival analysis was performed using the Kaplan–Meier method. Results Methylation profiling confirmed medulloblastoma in 51/52 cases; one case was reclassified as diffuse paediatric-type high-grade glioma, MYCN subtype. Among 51 methylation-confirmed cases, non-WNT/non-SHH tumors predominated (29/51; 56.9%), followed by SHH-activated (14/51; 27.5%) and WNT-activated (8/51; 15.7%). The routine three-marker panel (β-catenin/GAB1/YAP1) achieved 88.2% concordance (45/51), misclassifying 4 WNT-activated and 2 SHH-activated tumors. The extended seven-marker panel achieved 100% concordance (51/51) in this cohort, correctly assigning all molecular groups. LEF1 outperformed β-catenin for WNT detection (sensitivity 100% vs 50%). A minimal LEF1/GAB1 backbone achieved 98.0% concordance (50/51). MYC amplification was identified in 1/51 cases and MYCN amplification in 2/51 cases; FISH showed complete concordance with methylation-derived copy-number analysis. Conclusion An extended, stringently interpreted IHC panel provides accurate molecular grouping of medulloblastoma and represents a practical, resource-adapted diagnostic strategy where methylation profiling is not routinely feasible.

Neuro-Oncology Advances
All India Institute of Medical Sciences (IN)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon